全文获取类型
收费全文 | 72篇 |
免费 | 5篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 1篇 |
临床医学 | 14篇 |
内科学 | 2篇 |
皮肤病学 | 1篇 |
神经病学 | 1篇 |
外科学 | 14篇 |
综合类 | 19篇 |
预防医学 | 20篇 |
药学 | 12篇 |
中国医学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 1篇 |
2023年 | 12篇 |
2022年 | 5篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 6篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 6篇 |
2010年 | 2篇 |
2009年 | 4篇 |
2008年 | 16篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 1篇 |
2000年 | 2篇 |
排序方式: 共有91条查询结果,搜索用时 15 毫秒
1.
Objective To investigate the effect and mechanism by which PPARγ ligand, rosiglitasone, regulates the expression of CD40 and intercellular adhesion molecule 1 (ICAM-1) in the rat peritoneal mesothelial cells (RPMCs) induced by lipopolysaccharide (LPS). Methods RPMCs were harvested from Sprague-Dawley rat peritoneal cavity and maintained under defined in vitro conditions. The cells were randomly divided into groups as follows: medium, LPS (5 mg/L), LPS (5 mg/L)+BAY11-7085(5 μmol/L, NF-κB inhibitor), rosiglitazone (10 μmol/L or 20 μmol/L, peroxisome proliferator-activated receptor γ activator), LPS (5 mg/L)+rosiglitazone (10 μmol/L)+GW9662 (3 μmol/L, peroxisome proliferator-aetivatcd receptor γ antagonist), and LPS (5 mg/L)+vehicle (DMSO 0.2 ml/L). The expressions of CD40 and ICAM-1 RNA in RPMCs were examined by RT-PCR after 3 hour treatment, and the protein expressions of CD40, ICAM-1, p-NF-κB p65 and p-IκBα were examined by Western blot or immunofluorescence after 24 hour treatment. Results Following treatment with LPS, both the expressions of CD40 and ICAM-1 protein in RPMCs were up-regulated significantly (P<0.05), and the phosphoralation of p65 was increased greatly (1.10±0.17 vs 0.55±0.06, P<0.05). BAY11-7085 (5 μmol/L) significantly decreased the protein expression of p-p65 (0.22±0.11 vs 1.10±0.17, P<0.01), CD40 (0.34±0.02 vs 0.50±0.06, P<0.05) and ICAM-1 (0.35±0.16 vs 0.74±0.03, P<0.05). Pretreated with rosiglitazone for 3 h then added with LPS for 1 h, the levels of p-p65, CD40 and ICAM-1 in RPMCs were significantly decreased compared with those of LPS group (0.77±0.08 vs 0.90±0.10, P相似文献
2.
目的探讨老年高级别胶质瘤患者的临床特点和治疗方案。方法回顾性分析2012年4月至2017年8月中国医学科学院,北京协和医院神经外科连续收治的32例老年高级别胶质瘤患者的临床资料,总结其临床表现、术前Karnofsky功能状态评分(KPS)、合并症情况(查尔森合并症指数)、肿瘤病理学分型、治疗方法以及患者的总生存期。所有患者均行手术切除肿瘤或活组织检查术,术后辅以放化疗、单纯化疗或靶向治疗。采用Kaplan-Meier法探讨手术方式、合并症情况以及术前KPS对患者总生存期的影响。结果32例患者中,男21例,女11例;年龄为(71.9±6.9)岁(65~79岁);其中世界卫生组织(WHO)Ⅳ级(胶母细胞瘤)22例(68.7%),Ⅲ级10例(31.3%);术前中位KPS(范围)为78.1分(40~90分);中位查尔森合并症指数(范围)为5.7(4~8)。32例患者中,行病灶切除术21例(65.6%),行活组织检查术11例(34.4%)。术后行标准Stupp方案治疗7例,行替莫唑胺辅助化疗9例,行靶向治疗1例,未行进一步治疗11例。失访4例。32例患者的总生存期为1.2~73.3个月,中位值为15.8个月。生存分析结果表明,手术方式、术前KPS以及查尔森合并症指数并非患者总生存期的影响因素(均P>0.05)。结论老年高级别胶质瘤患者的一般情况较差,合并症多,通过采用手术、放化疗等综合治疗后生存期仍较短。在进行治疗方案的选择时,应根据患者的具体情况选择相对有利的治疗方案。 相似文献
3.
4.
5.
6.
7.
8.
Objective To investigate the effect and mechanism by which PPARγ ligand, rosiglitasone, regulates the expression of CD40 and intercellular adhesion molecule 1 (ICAM-1) in the rat peritoneal mesothelial cells (RPMCs) induced by lipopolysaccharide (LPS). Methods RPMCs were harvested from Sprague-Dawley rat peritoneal cavity and maintained under defined in vitro conditions. The cells were randomly divided into groups as follows: medium, LPS (5 mg/L), LPS (5 mg/L)+BAY11-7085(5 μmol/L, NF-κB inhibitor), rosiglitazone (10 μmol/L or 20 μmol/L, peroxisome proliferator-activated receptor γ activator), LPS (5 mg/L)+rosiglitazone (10 μmol/L)+GW9662 (3 μmol/L, peroxisome proliferator-aetivatcd receptor γ antagonist), and LPS (5 mg/L)+vehicle (DMSO 0.2 ml/L). The expressions of CD40 and ICAM-1 RNA in RPMCs were examined by RT-PCR after 3 hour treatment, and the protein expressions of CD40, ICAM-1, p-NF-κB p65 and p-IκBα were examined by Western blot or immunofluorescence after 24 hour treatment. Results Following treatment with LPS, both the expressions of CD40 and ICAM-1 protein in RPMCs were up-regulated significantly (P<0.05), and the phosphoralation of p65 was increased greatly (1.10±0.17 vs 0.55±0.06, P<0.05). BAY11-7085 (5 μmol/L) significantly decreased the protein expression of p-p65 (0.22±0.11 vs 1.10±0.17, P<0.01), CD40 (0.34±0.02 vs 0.50±0.06, P<0.05) and ICAM-1 (0.35±0.16 vs 0.74±0.03, P<0.05). Pretreated with rosiglitazone for 3 h then added with LPS for 1 h, the levels of p-p65, CD40 and ICAM-1 in RPMCs were significantly decreased compared with those of LPS group (0.77±0.08 vs 0.90±0.10, P相似文献
9.
目的通过成分献血(机采血小板)者与全血献血者体内血浆D-二聚体含量的比对观察,探讨二者在降低血栓性心脑血管疾病发生意义上的临床价值。方法采用全自动血凝分析透视光免疫浊度法对不同年龄段的360名健康献血者,进行体内血浆D-二聚体的含量测定,并进行比对观察。结果180名成分献血(机采血小板)者体内D-二聚体的含量显著低于180名全血献血者,2组献血者不同年龄血浆D-二聚体含量差异均有统计学意义(P〈0.01)。结论在降低血栓性疾病发生意义上,成份献血更优于传统的全血献血。 相似文献
10.
目的:研究石榴皮中总黄酮的微波提取最佳工艺条件并测定其含量。方法:采用微波提取法提取石榴皮中总黄酮,通过单因素试验,考察了微波功率、乙醇体积分数、料液比、微波提取时间4个因素对总黄酮提取的影响,通过正交试验进一步优化提取工艺,运用硝酸铝显色法测定总黄酮含量。结果:微波提取法提取石榴皮中总黄酮的最佳工艺为乙醇体积分数60%,料液比为1∶25,微波提取时间为120 s;微波功率对总黄酮提取无显著影响,其余3个因素对总黄酮提取的影响依次为乙醇体积分数>料液比>微波提取时间;总黄酮平均含量为6.70%。结论:采用微波提取法提取石榴皮中的总黄酮,具有快速、高效、节能、不破坏有效成分等特点,具有良好的应用前景。 相似文献